Condition
Diabetes Mellitus, Type 2
Obesity
Locations
China
Start date
26/05/2025
Identifiers
Trial ID
NN9541-4918,
NCT number NCT07004322,
Eudract number Not Available
NCT number NCT07004322,
Eudract number Not Available
Summary
Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight. In this study, the concentration of NNC0519-0130 in the blood will be measured and its safety will be evaluated. The participants will either get NNC0519-0130 or placebo (a "dummy" substance), which treatment the participants get is decided by chance. This study will test up to 7 different doses of NNC0519-0130 and will last for about 28 weeks.
Trial Overview:
Treatment
DRUG: NNC0519-0130
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
May 26 2025 - Apr 07 2026
Participants
20
Phase
I
Are you eligible?
Gender
MALE
Age
18 to 55 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.